Ishiguro Hiroaki, Hashimoto Tatsuo, Akata Mariko, Suzuki Shota, Azushima Kengo, Kobayashi Yusuke, Kanaoka Tomohiko, Yoshida Shinichiro, Wakui Hiromichi, Oshikawa Jin, Nagahama Kiyotaka, Inayama Yoshiaki, Tamura Kouichi, Toya Yoshiyuki, Umemura Satoshi
Department of Medical Science and Cardiorenal Medicine, Yokohama City University School of Medicine, Japan.
Intern Med. 2013;52(10):1079-83. doi: 10.2169/internalmedicine.52.9325. Epub 2013 May 15.
The case of a 68-year-old woman with purpura nephritis associated with nephrotic syndrome is herein described. The patient's clinical course and the findings of a renal biopsy study revealed purpura nephritis. Following treatment with corticosteroids and intravenous cyclophosphamide accompanied by an angiotensin II type I receptor-blocker, an anti-platelet drug and an hydroxymethylglutaryl (HMG)-CoA, the proteinuria mildly decreased. Additional rituximab therapy led to a complete remission. This report describes our successful experience using rituximab to treat refractory nephrotic syndrome of purpura nephritis. Further studies are required to confirm the efficacy of rituximab as an alternative therapy for nephrotic syndrome.
本文描述了一例68岁患有紫癜性肾炎合并肾病综合征的女性病例。患者的临床病程及肾活检研究结果显示为紫癜性肾炎。在使用皮质类固醇、静脉注射环磷酰胺,并联合血管紧张素II 1型受体阻滞剂、抗血小板药物及羟甲基戊二酰辅酶A(HMG-CoA)治疗后,蛋白尿略有减少。额外的利妥昔单抗治疗导致完全缓解。本报告描述了我们使用利妥昔单抗治疗紫癜性肾炎难治性肾病综合征的成功经验。需要进一步研究以证实利妥昔单抗作为肾病综合征替代疗法的疗效。